Trials / Completed
CompletedNCT02154646
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and side effects of LY2157299 in combination with gemcitabine in Japanese participants with pancreatic cancer that is advanced or has spread to another part of the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2157299 | Administered orally |
| DRUG | Gemcitabine | Administered IV |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2014-09-01
- Completion
- 2015-07-01
- First posted
- 2014-06-03
- Last updated
- 2016-02-10
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02154646. Inclusion in this directory is not an endorsement.